<DOC>
	<DOCNO>NCT02575651</DOCNO>
	<brief_summary>Fluzoparib oral potent , selective PARP-1 PARP-2 inhibitor . The objective study investigate safety tolerability Fluzoparib Capsule give orally Chinese patient advance solid malignancy . In addition , pharmacokinetic profile , MTD ( possible ) efficacy Fluzoparib investigate .</brief_summary>
	<brief_title>A Phase I Study Fluzoparib Patient With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>ECOG performance status 0 1 . Life expectancy 12 week . At least one measurable lesion exists . ( RECIST 1.1 ) . Subjects diagnose advanced solid malignancy refractory standard therapy standard therapy exists . Subjects overall good overall general condition . Signed informed consent . Subjects receive previous treatment PARP inhibitor . Less 4 week last clinical trial . Less 4 week last radiotherapy , chemotherapy , surgery , hermone treatment target therapy . Subjects unable swallow , dysfunction gastrointestinal absorption . Subjects symptomatic uncontrolled brain metastasis . Subjects uncontrolled hypokalemia hypomagnesemia study entry . Subjects know hypersensitivity Fluzoparib excipients product . Ongoing infection ( determined investigator ) . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . Subjects interrupt use drug may cause QT prolongation study . Subjects heart disease , include : ( 1 ) angina ; ( 2 ) require medication clinically significant arrhythmia ; ( 3 ) myocardial infarction ; ( 4 ) heart failure ; ( 5 ) Any heart disease judge investigator unsuitable participate trial . Female patient pregnancy , lactation woman childbearing potential test positive baseline pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PARP</keyword>
	<keyword>Advanced Solid Malignancies</keyword>
	<keyword>Fluzoparib</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>BRCA</keyword>
</DOC>